BALL BRYAN 4

What Happened
Bryan Ball, Chief Technical Operations Officer of Whitehawk Therapeutics, received an award/grant of 51,020 shares on May 14, 2026. The reported acquisition price was $3.92 per share for a total value of $199,998 (transaction code A — award/grant). This was a compensation award (an acquisition via grant), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Price per share: $3.92; Total value: $199,998.
• Filing date: Form 4 filed 2026-05-18 (filed within the standard two business‑day window).
• Shares owned after transaction: not specified in the provided filing details.
• Insider role shown on filing: Chief Technical Operations Officer (Bryan Ball).
• Footnotes/vesting: the Form 4 excerpt provided does not specify vesting, restrictions, or whether shares are immediately transferable.

Context
An "A" coded transaction typically reflects a compensation grant (e.g., restricted stock or RSUs) and is different from an insider buying shares on the open market. Such awards align executive compensation with company performance but do not necessarily signal a personal cash investment by the insider. For a fuller view, check the complete Form 4 for vesting terms or additional notes.